Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
NeoImmuneTech
Providence Health & Services
Royal Marsden NHS Foundation Trust
University of Michigan Rogel Cancer Center
University of Pittsburgh
Roswell Park Cancer Institute
University of California, Davis
Teva Branded Pharmaceutical Products R&D, Inc.
Cytovation AS
University of California, Davis
Takeda
Big Ten Cancer Research Consortium
H. Lee Moffitt Cancer Center and Research Institute
Seagen Inc.
Acerta Pharma BV
Takeda
Cytovation AS
M.D. Anderson Cancer Center
University of California, San Diego
BerGenBio ASA
Eisai Inc.
Incyte Corporation
University of Washington
Genexine, Inc.
Mayo Clinic
City of Hope Medical Center
Mayo Clinic
Mayo Clinic
Triumvira Immunologics, Inc.
Washington University School of Medicine
Sanofi
M.D. Anderson Cancer Center
Mayo Clinic
Aprea Therapeutics
Cedars-Sinai Medical Center
Syndax Pharmaceuticals
Hoosier Cancer Research Network
MacroGenics
University of Colorado, Denver
Providence Health & Services
Achilles Therapeutics UK Limited
Imperial College London
Fred Hutchinson Cancer Center
Intensity Therapeutics, Inc.
University of California, San Francisco
University of Washington
Sellas Life Sciences Group
Atara Biotherapeutics
University of Colorado, Denver